Controlled release pharmaceutical compositions with improved bioavailabililty
AssigneeRubicon Research Private Limited
InventorsPratibha S. Pilgaonkar, Anilkumar S. Gandhi
Life of this patent
Estimating the term…
Abstract
The present invention provides a controlled release oral pharmaceutical composition having a therapeutically effective amount of one or more pharmacologically active agent having low bioavailability; one or more solubilizers; one or more biocompatible swelling agents; and a swelling enhancer. The swelling agent, in combination with swelling enhancer, swells in the presence of water in gastric fluid such that the size of the dosage form is sufficiently increased to provide retention of the dosage form in the stomach of a patient, which gradually erodes within the gastrointestinal tract over a prolonged time period.
Claims29
1-32. (canceled)
A gastro-retentive oral dosage form, comprising:
- (a) a therapeutically effective amount of the drug valsartan,
- (b) one or more solubilizers,
- (c) one or more biocompatible swelling agents, and
- (d) one or more swelling enhancers,
- wherein the one or more swelling agents, in combination with the one or more swelling enhancers, swell in the presence of gastric fluid such that the size of the dosage form is sufficiently increased to provide whole or partial retention of the dosage form in the stomach of a patient, and gradually erode within the gastrointestinal tract over a prolonged period of time.
A gastroretentive oral dosage form comprising:
- (a) a therapeutically effective amount of valsartan,
- (b) one or more solubilizers to solubilize the drug, wherein the solubilizers comprise at least polyoxyethylene-polyoxypropylene block copolymer,
- (c) one or more biocompatible swelling agents, wherein at least one of the one or more swelling agents comprise polyethylene oxide, and
- (d) at least one swelling enhancer, wherein the at least one swelling enhancer comprises crospovidone,
- wherein the one or more swelling agents, in combination with the at least one swelling enhancer, swell in the presence of gastric fluid such that the size of the dosage form is sufficiently increased to provide whole or partial retention of the dosage form in the stomach of a patient, and gradually erode within the gastrointestinal tract over a prolonged period of time.
Dependencies are inferred from the claim text.